Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Chronic Fatigue of Post-COVID Condition

Trial statusAvailable

Trial phaseNot listed

Trial typeExpanded Access

Biological sexAll

Age18+

SponsorStemCyte, Inc.

About this trial

REGENECYTE® (HPC, Cord Blood (Hematopoietic Progenitor Cell, Cord Blood)) for treatment in patients with post-COVID.

This trial does not accept healthy volunteers

Male or female aged ≥ 18

With post-COVID condition

Has had a recent (within 7 days) negative SARS-CoV-2 test (an approved PCR (polyermerase chain reaction) or antigen test)

Not eligible for participation in any ongoing clinical trials of post-COVID condition with REGENECYTE

Neurological disorders prior to COVID-19 diagnosis

With pre-existing terminal illness

With known immune disease

Is pregnant or breastfeeding

REGENECYTE®
Biological/Vaccine
HPC, Cord Blood (Hematopoietic Progenitor Cell, Cord Blood)

No treatment groups listed

This trial has no outcomes listed.

Click on the lead sponsor to view all of their trials.

StemCyte, Inc.

Lead sponsor